EUVIMEDEUVIMED entdecken
Open Access

Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network

Mark W Tenforde iD, Zachary A Weber, Malini B DeSilva, Edward Stenehjem, Duck-Hye Yang, Bruce Fireman, Manjusha Gaglani iD, Noah Kojima, Stephanie A Irving, Suchitra Rao, Shaun J Grannis, Allison L Naleway und 24 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Mark W Tenforde und 35 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza A Virus, H1N1 Subtype, COVID-19, Influenza Vaccines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Following historically low influenza activity during the 2020–2021 season, the United States saw an increase in influenza circulating during the 2021–2022 season. Most viruses belonged to the influenza A(H3N2) 3C.2a1b 2a.2 subclade.

Methods

We conducted a test-negative case-control analysis among adults ≥18 years of age at 3 sites within the VISION Network. Encounters included emergency department/urgent care (ED/UC) visits or hospitalizations with ≥1 acute respiratory illness (ARI) discharge diagnosis codes and molecular testing for influenza. Vaccine effectiveness (VE) was calculated by comparing the odds of influenza vaccination ≥14 days before the encounter date between influenza-positive cases (type A) and influenza-negative and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–negative controls, applying inverse probability-to-be-vaccinated weights, and adjusting for confounders.

Results

In total, 86 732 ED/UC ARI-associated encounters (7696 [9%] cases) and 16 805 hospitalized ARI-associated encounters (649 [4%] cases) were included. VE against influenza-associated ED/UC encounters was 25% (95% confidence interval (CI), 20%–29%) and 25% (95% CI, 11%–37%) against influenza-associated hospitalizations. VE against ED/UC encounters was lower in adults ≥65 years of age (7%; 95% CI, −5% to 17%) or with immunocompromising conditions (4%; 95% CI, −45% to 36%).

Conclusions

During an influenza A(H3N2)-predominant influenza season, modest VE was observed. These findings highlight the need for improved vaccines, particularly for A(H3N2) viruses that are historically associated with lower VE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza A Virus, H1N1 SubtypeCOVID-19Influenza VaccinesAdultHumansUnited StatesChild, PreschoolInfluenza A Virus, H3N2 SubtypeSeasonsVaccine EfficacySARS-CoV-2VaccinationEmergency Service, HospitalAmbulatory CareHospitalsCase-Control Studies

Stichwörter der Autor:innen

COVID-19biasinfluenzatest-negative designvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Westat, Rockville, Maryland, USA.
  • HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA.
  • Department of Pediatrics, Section of Pediatric Infectious Diseases, Baylor Scott and White Health, Temple, Texas, USA.

ORCID-Profile: Mark W Tenforde, Manjusha Gaglani, Karthik Natarajan, Ousseny Zerbo, John Hansen

Förderung

  • Intramural CDC HHS
  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Tenforde, M. W., Weber, Z. A., DeSilva, M. B., Stenehjem, E., Yang, D. H., Fireman, B., Gaglani, M., Kojima, N., Irving, S. A., Rao, S., Grannis, S. J., Naleway, A. L., Kirshner, L., Kharbanda, A. B., Dascomb, K., Lewis, N., Dalton, A. F., Ball, S. W., Natarajan, K., …, & Klein, N. P. (2023). Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad015

Vancouver

Tenforde MW, Weber ZA, DeSilva MB, Stenehjem E, Yang DH, Fireman B, et al. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad015

BibTeX
@article{Tenforde2023,
  author = {Tenforde, Mark W and Weber, Zachary A and DeSilva, Malini B and Stenehjem, Edward and Yang, Duck-Hye and Fireman, Bruce and Gaglani, Manjusha and Kojima, Noah and Irving, Stephanie A and Rao, Suchitra and Grannis, Shaun J and Naleway, Allison L and Kirshner, Lindsey and Kharbanda, Anupam B and Dascomb, Kristin and Lewis, Ned and Dalton, Alexandra F and Ball, Sarah W and Natarajan, Karthik and Ong, Toan C and Hartmann, Emily and Embi, Peter J and McEvoy, Charlene E and Grisel, Nancy and Zerbo, Ousseny and Dunne, Margaret M and Arndorfer, Julie and Goddard, Kristin and Dickerson, Monica and Patel, Palak and Timbol, Julius and Griggs, Eric P and Hansen, John and Thompson, Mark G and Flannery, Brendan and Klein, Nicola P},
  title = {Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad015}
}
Kostenlos starten →